Novo Nordisk to Partner with Anthropic on AI-Driven Drug Discovery

Novo Nordisk has scheduled an announcement for September 16, 2026 that it will partner with Anthropic PBC to apply the company’s Claude AI models—particularly the Claude Science workbench—to accelerate drug discovery and AI-driven software development. The agreement will focus on identifying key research-and-development challenges, testing Claude Science in selected workflows, and deploying Anthropic’s frontier models to support biological reasoning and software engineering across Novo’s operations.

Novo Nordisk and Anthropic partner on AI research Novo Nordisk Taps Anthropic’s Claude to Speed Drug Discovery Novo Nordisk Turns to Anthropic's Claude to Accelerate Drug Discovery — BigGo Finance Novo Nordisk Partners With Anthropic to Accelerate Drug Discovery Using AI BioPharmaDiveNovo teams up with Anthropic to speed up drug discovery EuronewsBloombergPolitico Europe

The collaboration follows a broader industry push to embed artificial intelligence in drug development. Novo Nordisk previously integrated OpenAI tools across its organization in April 2026 and has invested in the Danish Centre for AI Innovation, which operates the Gefion supercomputer. Competitors such as Bristol Myers Squibb, Eli Lilly, Roche, Merck & Co., Takeda and others have announced AI deals with Nvidia, Google Cloud, Insilico Medicine and other providers.

BioPharmaDive

• Novo’s shares were little changed in Copenhagen trading at 3:30 p.m. on the day of the scheduled announcement; the stock has fallen about 15 % year-to-date.

Bloomberg

• Anthropic introduced the Claude Science workbench on June 30, 2026 as a public-beta platform that integrates more than 60 curated scientific skills and connectors for genomics, proteomics, structural biology and cheminformatics.

Novo Nordisk Taps Anthropic’s Claude to Speed Drug Discovery

• In a prior Anthropic case study, Novo’s internal Claude-based documentation tool reduced clinical-study-report generation time from over ten weeks to ten minutes and cut device-verification-protocol effort by roughly 95 %.

Novo Nordisk Taps Anthropic’s Claude to Speed Drug Discovery

Novo’s president and chief executive, Mike Doustdar, framed the partnership as a strategic step toward “supercharging” the company’s R&D organization and delivering “completely new scientific opportunities” that could compress the path from research to marketed product.

Novo Nordisk Turns to Anthropic's Claude to Accelerate Drug Discovery — BigGo Finance

Anthropic co-founder and CEO Dario Amodei highlighted the potential of frontier models to shorten research timelines, improve outcomes and enable the discovery of medicines that significantly improve human life. Both companies stressed that the initiative is intended to augment, not replace, human expertise in drug development.

Novo Nordisk Taps Anthropic’s Claude to Speed Drug Discovery

• “Joining forces with Anthropic will supercharge our R&D organization,” — Novo CEO Mike Doustdar

BioPharmaDive

• “AI’s increasing capability brings with it the potential to compress a century’s worth of biological and medical breakthroughs into a decade,” — Dario Amodei, CEO and co-founder

Euronews

• “Joining forces with Anthropic will supercharge our R&D organisation and help us on our mission to bring new, transformative health solutions to people living with chronic diseases,” — Mike Doustdar, novo CEO

Politico Europe

• September 16, 2026 – Novo Nordisk’s scheduled public announcement of the Anthropic partnership.

Bloomberg

• Post-announcement – Initial testing of Claude Science in identified R&D workflows, with subsequent scaling of AI-driven software development across the company.

Novo Nordisk Partners With Anthropic to Accelerate Drug Discovery Using AI

• Ongoing monitoring of data-governance and oversight mechanisms to address emerging ethical and safety concerns surrounding large-language-model applications in biomedicine.

Novo Nordisk and Anthropic partner on AI research